



**House Human Services Committee
HB 1033 – Relating to the Prescribing of Biosimilar Drugs
January 6, 2021 – 10:45 am
PCMA Testimony in Support of HB 1033**

CHAIRMAN WEISZ AND COMMITTEE MEMBERS:

My name is Michelle Mack and I represent the Pharmaceutical Care Management Association, commonly referred to as PCMA. PCMA is the national trade association for pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 266 million Americans with health coverage provided by large and small employers, health insurers, labor unions, and federal and state-sponsored health programs.

PCMA supports HB 1033, and is encouraged by the revisions to the biosimilar drug dispensing statute. These revisions meet the goal of removing barriers to the use of biosimilar medications. The language pertaining to notification in the bill is what has been adopted in the vast majority of the country and modifies the current notification requirement so it can be done via various means, including electronic transmissions.

Thank you for your time and consideration. I would be happy to answer any questions.

Sincerely,

A handwritten signature in blue ink that reads "Michelle D. Mack".

Michelle Mack
Director, State Affairs
Phone: (202) 579-3190
Email: mmack@pcmanet.org